[go: up one dir, main page]

DE69837211D1 - Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis - Google Patents

Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Info

Publication number
DE69837211D1
DE69837211D1 DE69837211T DE69837211T DE69837211D1 DE 69837211 D1 DE69837211 D1 DE 69837211D1 DE 69837211 T DE69837211 T DE 69837211T DE 69837211 T DE69837211 T DE 69837211T DE 69837211 D1 DE69837211 D1 DE 69837211D1
Authority
DE
Germany
Prior art keywords
enzephalitis
japanese
virus
vero cells
vaccinate against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837211T
Other languages
English (en)
Other versions
DE69837211T2 (de
Inventor
Hyun Su Kim
Wang Don Yoo
Soo Ok Kim
Sung Hee Lee
Sang Bum Moon
Sun Pyo Hong
Yong Cheol Shin
Yong Ju Chung
Kenneth H Eckels
Bruce Innis
Joseph R Putnak
Leonard N Binn
Ashok K Srivastava
Doria R Dubois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ Corp
Walter Reed Army Institute of Research
United States Department of the Army
Original Assignee
CJ Corp
Walter Reed Army Institute of Research
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ Corp, Walter Reed Army Institute of Research, United States Department of the Army filed Critical CJ Corp
Priority to DE122009000037C priority Critical patent/DE122009000037I2/de
Application granted granted Critical
Publication of DE69837211D1 publication Critical patent/DE69837211D1/de
Publication of DE69837211T2 publication Critical patent/DE69837211T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69837211T 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis Expired - Lifetime DE69837211T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE122009000037C DE122009000037I2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR4200297 1997-08-28
KR19970042001 1997-08-28
KR4200197 1997-08-28
KR19970042002 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
DE69837211D1 true DE69837211D1 (de) 2007-04-12
DE69837211T2 DE69837211T2 (de) 2007-12-06

Family

ID=26633032

Family Applications (2)

Application Number Title Priority Date Filing Date
DE122009000037C Active DE122009000037I2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis
DE69837211T Expired - Lifetime DE69837211T2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE122009000037C Active DE122009000037I2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Country Status (15)

Country Link
US (1) US6309650B1 (de)
EP (2) EP1025209B1 (de)
JP (1) JP4161017B2 (de)
KR (1) KR100314404B1 (de)
CN (1) CN1142271C (de)
AU (1) AU748730B2 (de)
CA (1) CA2301000C (de)
DE (2) DE122009000037I2 (de)
DK (2) DK1025209T3 (de)
ES (2) ES2281929T3 (de)
FR (1) FR09C0037I2 (de)
MY (1) MY129773A (de)
NL (1) NL300391I2 (de)
NZ (1) NZ503522A (de)
WO (1) WO1999011762A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
WO2000020565A1 (fr) * 1998-10-05 2000-04-13 The Research Foundation For Microbial Diseases Of Osaka University Immunogene ameliore pour un vaccin inactive contre une infection a virus de l'encephalite japonaise et procede de production associe
EP1183332B1 (de) * 1999-04-22 2010-07-14 United States Department Of Agriculture Auf dem isolat ja-142 basierender impfstoff gegen das reproduktive-und-respiratorische syndrom beim schwein
WO2001076624A1 (fr) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vaccin inactive contre l'encephalite japonaise b et procede d'elaboration associe
CA2451816A1 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN101343625A (zh) * 2004-02-23 2009-01-14 克鲁塞尔荷兰公司 病毒纯化方法
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
CA2676775A1 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
EP2233151B1 (de) * 2007-12-26 2016-05-11 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Verfahren zur herstellung eines impfstoffs gegen japanische enzephalitis virus, der über lange zeit stabil haltbar ist, und anwendung des impfstoffs
US9114098B2 (en) 2008-06-04 2015-08-25 The Chemo-Sero-Therapeutic Research Institute Method for using inactivated Japanese encephalitis virus particles as adjuvant
KR101622738B1 (ko) * 2008-07-30 2016-05-19 히사미쓰 세이야꾸 가부시키가이샤 마이크로니들 디바이스 및 마이크로니들 디바이스에 의한 일본 뇌염 바이러스 항원의 주효성을 상승시키는 방법
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
PL3269386T3 (pl) 2011-12-06 2022-12-05 Valneva Austria Gmbh Związki glinu do stosowania w środkach terapeutycznych i szczepionkach
AU2014338520B2 (en) * 2013-09-14 2019-12-05 Bharat Biotech International Limited A viral vaccine and methods of manufacture thereof
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
CN115381934A (zh) * 2015-12-23 2022-11-25 瓦尔尼瓦奥地利有限责任公司 Zika病毒疫苗
CA3010049C (en) * 2016-01-15 2021-10-12 The Chemo-Sero-Therapeutic Research Institute Vaccine containing immobilized virus particles
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
JP7301811B2 (ja) 2017-09-21 2023-07-03 ヴァルネヴァ エスイー 免疫原性チクングニアウイルスｃｈｉｋｖ－ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法
EP3703739A2 (de) 2017-11-03 2020-09-09 Takeda Vaccines, Inc. Zika-impfstoffe und immunogene zusammensetzungen und verfahren zu ihrer verwendung
EP3717638A4 (de) 2017-11-30 2022-03-09 Takeda Vaccines, Inc. Verfahren zur inaktivierung von zika virus und verwandte verfahren
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
EP3845639A4 (de) * 2018-08-27 2022-05-11 Mican Technologies Inc. Verfahren zur bewertung von antiinfektiva, impfstoffen etc. unter verwendung von immortalisierten monozytischen zellen und induzierten zellen
EP3895729A1 (de) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanter sars-cov-2-virus-impfstoff
AU2021229710A1 (en) 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
US20230110516A1 (en) 2020-03-01 2023-04-13 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
JP2024541677A (ja) * 2022-04-20 2024-11-08 コリア ナショナル インスティテュート オブ ヘルス 高力価日本脳炎ウイルス遺伝子型ｖ型及びその使用
WO2024153686A1 (en) 2023-01-18 2024-07-25 Valneva Austria Gmbh Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (de) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Lebender Impfstoff gegen Getah Virus infektiöse Krankheiten, und dreiwertiger lebender Impfstoff gegen japanische Enkephalitis Virus, Schweinparvovirus und Getah Virus
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
MY129773A (en) 2007-04-30
WO1999011762A1 (en) 1999-03-11
FR09C0037I1 (de) 2009-09-25
EP1025209B1 (de) 2007-02-28
EP1604685A2 (de) 2005-12-14
JP2001514844A (ja) 2001-09-18
DE69837211T2 (de) 2007-12-06
EP1025209A1 (de) 2000-08-09
AU9004798A (en) 1999-03-22
EP1604685A3 (de) 2006-07-05
FR09C0037I2 (fr) 2021-11-05
ES2281929T3 (es) 2007-10-01
NZ503522A (en) 2001-06-29
DE122009000037I1 (de) 2009-11-05
KR19990023955A (ko) 1999-03-25
EP1604685B1 (de) 2012-02-22
ES2382946T3 (es) 2012-06-14
JP4161017B2 (ja) 2008-10-08
CN1272879A (zh) 2000-11-08
CA2301000C (en) 2003-07-08
DK1604685T3 (da) 2012-06-18
DK1025209T3 (da) 2007-06-25
DE122009000037I2 (de) 2011-06-16
NL300391I1 (nl) 2009-08-03
KR100314404B1 (ko) 2002-10-12
CA2301000A1 (en) 1999-03-11
CN1142271C (zh) 2004-03-17
AU748730B2 (en) 2002-06-13
NL300391I2 (nl) 2009-11-02
US6309650B1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
DE69837211D1 (de) Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis
DE69803254D1 (de) Toner und Bildherstellungsverfahren
DE69815569D1 (de) Kehlkopfmaske
DE69819387D1 (de) Kehlkopfmaske
DE69818535D1 (de) Gegen unbefugte Handhabung gesicherte integrierte Schaltung
PT977503E (pt) Conjunto de fecho reutilizavel
ID21315A (id) Pancaran gas koheren
DE69841043D1 (de) Gassensor
DE69806477D1 (de) Mikrotechnologischer strömungs-optischer gassensor
DE69821410D1 (de) Gassensor
DE69840196D1 (de) Probenröhrchen
DE69921552D1 (de) Toner und Bildherstellungsverfahren
DE69841187D1 (de) Gassensor
DE69820345D1 (de) Entwicklungskartusche und elektrophotographisches Bilderzeugungsgerät
DE69926032D1 (de) Prozesskartusche und elektrophotographisches Gerät
DE69838513D1 (de) Verkürztes hepatitis-c-virus protein nsb5 und methoden, um antivirale substanzen zu identifizieren
DE69840156D1 (de) Gassensor
DE69922099D1 (de) Elektrophotographisches lichtempfindliches Element, Prozesskartusche und elektrophotographisches Gerät
FI980472L (fi) Latausmenetelmä ja -järjestely
NO993298L (no) Ny fremgangsmÕte
DE69841009D1 (de) Gassensor
NO20011843D0 (no) Selektivt replikerende virusvektorer
DE69825615D1 (de) Gaseinführung
IS1780B (is) théttilok fyrir gashylki
NO995796D0 (no) Ny fremgangsmåte